Cell Therapy for Age-Related Disorders: Myocardial Infarction and Stroke – A Mini-Review
Authors:
- Brent A. WilliamsBWBrent A. Williams
- Armand KeatingAKArmand Keating
- 15 September 2008
- journal article
- review article
- Published by S. Karger AG in Gerontology
- Vol. 54 (5) , 300-311
Abstract
Background: The leading causes of death and disability in the elderly are from cardiovascular and cerebrovascular diseases. The biological role of stem cells in the hematopoietic system has been well characterized and has led to the development of hematopoietic stem and progenitor cell (HSPC) transplantation for the treatment of numerous malignant and nonmalignant diseases. More recently, stem cells have been found in many other tissues of the body including the heart and brain. As the field of stem cell biology has progressed, cell therapies for the treatment of myocardial infarction and stroke have been tested in early stage clinical trials using a variety of cellular agents. Objective: To review the clinical evidence supporting the role of cell therapies for myocardial infarction and stroke. Methods: A systematic review of the literature was conducted to identify clinical trials using cell therapies for myocardial infarction and stroke. Results: Clinical trials of granulocyte colony-stimulating factor to mobilize HSPC after percutaneous coronary intervention for acute myocardial infarction have not shown clinical benefit. Direct delivery of HSPC to coronary arteries supplying the infarcted region using percutaneous coronary intervention does improve hemodynamic endpoints such as left ventricular ejection fraction in many studies. One randomized trial demonstrated improvement in clinically meaningful endpoints such as death, recurrence of myocardial infarction and re-hospitalization for heart failure. Several small trials of cell therapy for stroke have been reported, including cytokine-mobilized HSPC, mesenchymal stromal cells and cell lines transplanted stereotactically into the region affected by stroke. Conclusions: In some prospective randomized trials, cell therapy for myocardial infarction leads to improvement in hemodynamic parameters. Cell therapy for stroke is a relatively new area of translational and clinical research with preliminary studies showing safety and some measurable benefit in small numbers of subjects.Keywords
This publication has 11 references indexed in Scilit:
- Can concurrent core biopsy and fine needle aspiration biopsy improve the false negative rate of sonographically detectable breast lesions?BMC Cancer, 2010
- Clinicopathologic study of 53 metaplastic breast carcinomas: their elements and prognostic implicationsHuman Pathology, 2010
- Worse prognosis of metaplastic breast cancer patients than other patients with triple-negative breast cancerBreast Cancer Research and Treatment, 2010
- Use of imprint cytology for assessment of surgical margins in lumpectomy specimens of breast cancer patientsDiagnostic Cytopathology, 2007
- Metaplastic carcinoma of the breast, an unusual disease with worse prognosis: the experience of the European Institute of Oncology and review of the literatureBreast Cancer Research and Treatment, 2006
- Metaplastic breast carcinomas are basal‐like tumoursHistopathology, 2006
- Observation of tumour thickness and resection margin at surgical excision of primary oral squamous cell carcinoma—assessment by ultrasoundInternational Journal of Oral and Maxillofacial Surgery, 2006
- Touch imprint cytologic preparations and the diagnosis of head and neck mass lesionsAnnals of Oncology, 2005
- Vasa Previa: The Impact of Prenatal Diagnosis on OutcomesObstetrics & Gynecology, 2004
- Review of the literature and a recommended system of malignancy grading in oral squamous cell carcinomasEuropean Journal of Oral Sciences, 1987